{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:27:07Z","timestamp":1790684827703,"version":"4.1.0"},"reference-count":115,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>The Canadian Rheumatology Association (CRA) has developed recommendations for the pharmacological management of rheumatoid arthritis (RA) with traditional and biologic disease-modifying antirheumatic drugs (DMARD) in 2 parts. Part II, focusing on specific safety aspects of treatment with traditional and biologic DMARD in patients with RA, is reported here.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Key questions were identified<jats:italic>a priori<\/jats:italic>based on results of a national needs-assessment survey. A systematic review of all clinical practice guidelines and consensus statements regarding treatment with traditional and biologic DMARD in patients with RA published between January 2000 and June 2010 was performed in Medline, Embase, and CINAHL databases, and was supplemented with a \u201cgrey literature\u201d search including relevant public health guidelines. Systematic reviews of postmarketing surveillance and RA registry studies were performed to update included guideline literature reviews as appropriate. Guideline quality was independently assessed by 2 reviewers. Guideline characteristics, recommendations, and supporting evidence from observational studies and randomized trials were synthesized into evidence tables. The working group voted on recommendations using a modified Delphi technique.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Thirteen recommendations addressing perioperative care, screening for latent tuberculosis infection prior to the initiation of biologic DMARD, optimal vaccination practices, and treatment of RA patients with active or a history of malignancy were developed for rheumatologists, other primary prescribers of RA drug therapies, and RA patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>These recommendations were developed based on a synthesis of international RA and public health guidelines, supporting evidence, and expert consensus in the context of the Canadian health system. They are intended to help promote best practices and improve healthcare delivery for persons with RA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.120165","type":"journal-article","created":{"date-parts":[[2012,6,17]],"date-time":"2012-06-17T21:21:49Z","timestamp":1339968109000},"page":"1583-1602","source":"Crossref","is-referenced-by-count":119,"title":["Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety"],"prefix":"10.3899","volume":"39","author":[{"given":"CLAIRE","family":"BOMBARDIER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GLEN S.","family":"HAZLEWOOD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"POONEH","family":"AKHAVAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ORIT","family":"SCHIEIR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANNE","family":"DOOLEY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BOULOS","family":"HARAOUI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAJED","family":"KHRAISHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHARON A.","family":"LECLERCQ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JEAN","family":"L\u00c9GAR\u00c9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DIANNE P.","family":"MOSHER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JAMES","family":"PENCHARZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JANET E.","family":"POPE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOHN","family":"THOMSON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CARTER","family":"THORNE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHEL","family":"ZUMMER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHAEL A.","family":"GARDAM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JOHAN","family":"ASKLING","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VIVIAN","family":"BYKERK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2012,6,15]]},"reference":[{"key":"2018112909280749000_39.8.1583.1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110207"},{"key":"2018112909280749000_39.8.1583.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110208"},{"key":"2018112909280749000_39.8.1583.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2018112909280749000_39.8.1583.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"2018112909280749000_39.8.1583.5","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzi108"},{"key":"2018112909280749000_39.8.1583.6","unstructured":"Canadian Agency for Drugs and Technology in Health . Grey matters: A practical search tool for evidence-based medicine. Ottawa: Canadian Agency for Drugs and Technology in Health; 2009. [Internet. Accessed April 5, 2012.] Available from: http:\/\/www.cadth.ca\/en\/resources\/grey-matters"},{"key":"2018112909280749000_39.8.1583.7","doi-asserted-by":"publisher","DOI":"10.1136\/qhc.12.1.18"},{"key":"2018112909280749000_39.8.1583.8","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN) . SIGN 50: A guideline developer\u2019s handbook. Edinburgh: Scottish Intercollegiate Guidelines Network; 2008. [Internet. Accessed March 30, 2012.] Available from: http:\/\/www.sign.ac.uk\/guidelines\/fulltext\/50\/index.html"},{"key":"2018112909280749000_39.8.1583.9","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-5-23"},{"key":"2018112909280749000_39.8.1583.10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2000.00949.x"},{"key":"2018112909280749000_39.8.1583.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2006.10.003"},{"key":"2018112909280749000_39.8.1583.12","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.171"},{"key":"2018112909280749000_39.8.1583.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel216a"},{"key":"2018112909280749000_39.8.1583.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken450a"},{"key":"2018112909280749000_39.8.1583.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094474"},{"key":"2018112909280749000_39.8.1583.16","unstructured":"Spanish Society of Rheumatology . Update of the clinical practise guideline for the management of rheumatoid arthritis in Spain. Madrid: Sociedad Espanola de Reumatologia; 2007. [Internet. Accessed March 30, 2012.] Available from: http:\/\/www.ser.es\/practicaClinica\/Guias_Practica_Clinica.php"},{"key":"2018112909280749000_39.8.1583.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.3.214"},{"key":"2018112909280749000_39.8.1583.18","first-page":"1129","article-title":"Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis","volume":"20","author":"Sany","year":"1993","journal-title":"J Rheumatol"},{"key":"2018112909280749000_39.8.1583.19","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-005-0444-4"},{"key":"2018112909280749000_39.8.1583.20","first-page":"984","article-title":"Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis?","volume":"18","author":"Bridges","year":"1991","journal-title":"J Rheumatol"},{"key":"2018112909280749000_39.8.1583.21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3928\/0147-7447-19960301-09","article-title":"Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy","volume":"19","author":"Carpenter","year":"1996","journal-title":"Orthopedics"},{"key":"2018112909280749000_39.8.1583.22","unstructured":"Australian Rheumatology Association . Updated recommendations for the use of biological agents for the treatment of rheumatic diseases. Sydney: Australian Rheumatology Association; 2010. [Internet. Accessed April 2, 2012.] Available from: http:\/\/www.rheumatology.org.au\/downloads\/FINAL-biological-recommendations060111.pdf"},{"key":"2018112909280749000_39.8.1583.23","unstructured":"Devlin J Ramakrishnan SA Fitzgerald O for the Irish Society for Rheumatology (ISR) . Guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis. 2005."},{"key":"2018112909280749000_39.8.1583.24","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-009-0197-6"},{"key":"2018112909280749000_39.8.1583.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh464"},{"key":"2018112909280749000_39.8.1583.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-8077.2006.00194.x"},{"key":"2018112909280749000_39.8.1583.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1297-319X(10)70001-4"},{"key":"2018112909280749000_39.8.1583.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1297-319X(09)74520-8"},{"issue":"Suppl 1","key":"2018112909280749000_39.8.1583.29","first-page":"S1","article-title":"Rituximab (MabThera) therapy and safety management. Clinical tool guide","volume":"75","author":"Pham","year":"2008","journal-title":"Joint Bone Spine"},{"key":"2018112909280749000_39.8.1583.30","unstructured":"Royal College of Nursing (RCN) . Assessing, managing and monitoring biologic therapies for inflammatory arthritis: Guidance for rheumatology practitioners. London: Royal College of Nursing; 2009. [Internet. Accessed April 2, 2012.] Available from: http:\/\/www.rcn.org.uk\/__data\/assets\/pdf_file\/0004\/78565\/001984.pdf"},{"key":"2018112909280749000_39.8.1583.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.23721"},{"key":"2018112909280749000_39.8.1583.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2009.10.006"},{"key":"2018112909280749000_39.8.1583.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1297-319X(05)80001-6"},{"key":"2018112909280749000_39.8.1583.34","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.7.689"},{"key":"2018112909280749000_39.8.1583.35","doi-asserted-by":"publisher","DOI":"10.1002\/art.21841"},{"key":"2018112909280749000_39.8.1583.36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/107110070402500510","article-title":"Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy","volume":"25","author":"Bibbo","year":"2004","journal-title":"Foot Ankle Int"},{"key":"2018112909280749000_39.8.1583.37","first-page":"1153","article-title":"Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection","volume":"168","author":"Long","year":"2003","journal-title":"CMAJ"},{"key":"2018112909280749000_39.8.1583.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"2018112909280749000_39.8.1583.39","doi-asserted-by":"publisher","DOI":"10.1002\/art.21137"},{"key":"2018112909280749000_39.8.1583.40","doi-asserted-by":"publisher","DOI":"10.1002\/art.24476"},{"key":"2018112909280749000_39.8.1583.41","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona","year":"2003","journal-title":"J Rheumatol"},{"key":"2018112909280749000_39.8.1583.42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"2018112909280749000_39.8.1583.43","doi-asserted-by":"publisher","DOI":"10.1002\/art.22768"},{"key":"2018112909280749000_39.8.1583.44","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"key":"2018112909280749000_39.8.1583.45","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): Effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909280749000_39.8.1583.46","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"2018112909280749000_39.8.1583.47","doi-asserted-by":"publisher","DOI":"10.1002\/art.20009"},{"key":"2018112909280749000_39.8.1583.48","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.047274"},{"key":"2018112909280749000_39.8.1583.49","first-page":"CD008794","article-title":"Adverse effects of biologics: A network meta-analysis and Cochrane overview","volume":"2","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2018112909280749000_39.8.1583.50","unstructured":"Public Health Agency of Canada . Canadian Tuberculosis Standards 2007. Ottawa: Public Health Agency of Canada; 2007. [Internet. Accessed April 2, 2012.] Available from: http:\/\/www.phac-aspc.gc.ca\/tbpc-latb\/pubs\/tbstand07-eng.php"},{"key":"2018112909280749000_39.8.1583.51","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283474d62"},{"key":"2018112909280749000_39.8.1583.52","first-page":"498","article-title":"Thinking in three dimensions: A web-based algorithm to aid the interpretation of tuberculin skin test results","volume":"12","author":"Menzies","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2018112909280749000_39.8.1583.53","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei500"},{"key":"2018112909280749000_39.8.1583.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.10.001"},{"key":"2018112909280749000_39.8.1583.55","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.123885"},{"key":"2018112909280749000_39.8.1583.56","unstructured":"Guidelines and Protocols Advisory Committee . Rheumatoid arthritis: diagnosis and management; 2006. Victoria, BC: British Columbia Ministry of Health; 2006. [Internet. Accessed April 2, 2012.] Available from: http:\/\/www.bcguidelines.ca\/guideline_ra.html"},{"key":"2018112909280749000_39.8.1583.57","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181a90cd8"},{"key":"2018112909280749000_39.8.1583.58","doi-asserted-by":"publisher","DOI":"10.1016\/S0973-3698(10)60373-1"},{"key":"2018112909280749000_39.8.1583.59","unstructured":"National Institute for Clinical Excellence (NICE) . Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis: NICE technology appraisal guidance 130 (includes a review of technology appraisal guidance 36); 2007. London: National Institute for Health and Clinical Excellence. [Internet. Accessed April 2, 2012.] Available from: http:\/\/www.nice.org.uk\/nicemedia\/live\/11867\/37914\/37914.pdf"},{"key":"2018112909280749000_39.8.1583.60","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.061002"},{"key":"2018112909280749000_39.8.1583.61","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126532"},{"key":"2018112909280749000_39.8.1583.62","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.046797"},{"key":"2018112909280749000_39.8.1583.63","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126573"},{"key":"2018112909280749000_39.8.1583.64","first-page":"1","article-title":"Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection \u2014 United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"2018112909280749000_39.8.1583.65","doi-asserted-by":"publisher","DOI":"10.1086\/647944"},{"key":"2018112909280749000_39.8.1583.66","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq183"},{"key":"2018112909280749000_39.8.1583.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.12.003"},{"key":"2018112909280749000_39.8.1583.68","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei193"},{"key":"2018112909280749000_39.8.1583.69","first-page":"1","article-title":"General recommendations on immunization \u2014 Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","year":"2011","journal-title":"MMWR Recomm Rep"},{"key":"2018112909280749000_39.8.1583.70","unstructured":"National Advisory Committee on Immunization . Canadian immunization guide. 7th ed. Ottawa: Public Health Agency of Canada; 2006. Available from: http:\/\/www.phac-aspc.gc.ca\/publicat\/cig-gci\/"},{"key":"2018112909280749000_39.8.1583.71","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137216"},{"key":"2018112909280749000_39.8.1583.72","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken015a"},{"key":"2018112909280749000_39.8.1583.73","doi-asserted-by":"publisher","DOI":"10.1080\/17402520600800820"},{"key":"2018112909280749000_39.8.1583.74","doi-asserted-by":"publisher","DOI":"10.1086\/341403"},{"key":"2018112909280749000_39.8.1583.75","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.16.1769"},{"key":"2018112909280749000_39.8.1583.76","unstructured":"National Advisory Committee on Immunization . Statement on human papilloma virus vaccine 2007. Ottawa: Public Health Agency of Canada; 2007. [Internet. Accessed April 2, 2012.] Available from: http:\/\/www.phac-aspc.gc.ca\/publicat\/ccdr-rmtc\/07vol33\/acs-02\/index-eng.php"},{"key":"2018112909280749000_39.8.1583.77","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077552"},{"key":"2018112909280749000_39.8.1583.78","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel366"},{"key":"2018112909280749000_39.8.1583.79","doi-asserted-by":"publisher","DOI":"10.1086\/338043"},{"key":"2018112909280749000_39.8.1583.80","doi-asserted-by":"publisher","DOI":"10.1053\/j.semarthrit.2003.10.003"},{"key":"2018112909280749000_39.8.1583.81","first-page":"952","article-title":"Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone","volume":"34","author":"Visvanathan","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909280749000_39.8.1583.82","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077461"},{"key":"2018112909280749000_39.8.1583.83","doi-asserted-by":"publisher","DOI":"10.1002\/art.25033"},{"key":"2018112909280749000_39.8.1583.84","doi-asserted-by":"publisher","DOI":"10.1002\/art.25034"},{"key":"2018112909280749000_39.8.1583.85","doi-asserted-by":"publisher","DOI":"10.1186\/ar2404"},{"key":"2018112909280749000_39.8.1583.86","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f7c706"},{"key":"2018112909280749000_39.8.1583.87","doi-asserted-by":"publisher","DOI":"10.1002\/art.21675"},{"key":"2018112909280749000_39.8.1583.88","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"2018112909280749000_39.8.1583.89","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094904"},{"key":"2018112909280749000_39.8.1583.90","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2046"},{"key":"2018112909280749000_39.8.1583.91","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.149419"},{"key":"2018112909280749000_39.8.1583.92","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20129"},{"key":"2018112909280749000_39.8.1583.93","doi-asserted-by":"publisher","DOI":"10.1186\/ar2904"},{"key":"2018112909280749000_39.8.1583.94","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090856"},{"key":"2018112909280749000_39.8.1583.95","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.097527"},{"key":"2018112909280749000_39.8.1583.96","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20124"},{"key":"2018112909280749000_39.8.1583.97","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080878"},{"key":"2018112909280749000_39.8.1583.98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2004.10.010"},{"key":"2018112909280749000_39.8.1583.99","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2007.107"},{"key":"2018112909280749000_39.8.1583.100","doi-asserted-by":"publisher","DOI":"10.1002\/art.23716"},{"key":"2018112909280749000_39.8.1583.101","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2007.08.006"},{"key":"2018112909280749000_39.8.1583.102","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075986"},{"key":"2018112909280749000_39.8.1583.103","doi-asserted-by":"publisher","DOI":"10.1002\/art.20311"},{"key":"2018112909280749000_39.8.1583.104","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.085852"},{"key":"2018112909280749000_39.8.1583.105","doi-asserted-by":"publisher","DOI":"10.1002\/art.22056"},{"key":"2018112909280749000_39.8.1583.106","doi-asserted-by":"publisher","DOI":"10.1002\/art.22579"},{"key":"2018112909280749000_39.8.1583.107","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030528"},{"key":"2018112909280749000_39.8.1583.108","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033241"},{"key":"2018112909280749000_39.8.1583.109","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.117762"},{"key":"2018112909280749000_39.8.1583.110","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.07.006"},{"key":"2018112909280749000_39.8.1583.111","doi-asserted-by":"publisher","DOI":"10.1002\/art.22864"},{"key":"2018112909280749000_39.8.1583.112","doi-asserted-by":"publisher","DOI":"10.1002\/art.24941"},{"key":"2018112909280749000_39.8.1583.113","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102103"},{"key":"2018112909280749000_39.8.1583.114","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033993"},{"key":"2018112909280749000_39.8.1583.115","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.06.013"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.120165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T05:41:11Z","timestamp":1642484471000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.120165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,15]]},"references-count":115,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2012,8,1]]},"published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.3899\/jrheum.120165"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.120165","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,15]]}}}